Skip to main content
SpringerLink
Log in

Systemic Treatments and Related Side Effects in Liver Tumors

  • Chapter
  • First Online:
Radionuclide Therapy

  • 476 Accesses

Abstract

Mass formation in the liver is a common condition, but most of these masses are benign. Benign formations in the liver may include mass formations originating from the liver parenchyma such as focal nodular hyperplasia, nodular regenerative hyperplasia, hepatocellular adenoma, and regenerative and dysplastic nodules, as well as mass formations originating from the bile ducts such as simple cyst, biliary hamartoma, biliary adenoma, or biliary cystadenoma. Vascular benign masses originating from mesenchymal tissues can also be observed [1, 2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bahirwani R, Reddy KR. Review article: the evaluation of solitary liver masses. Aliment Pharmacol Ther. 2008;28(8):953–65.

    CAS  PubMed  Google Scholar 

  2. Paredis V. Benign liver tumors: an update. Clin Liver Dis. 2010;14(4):719–29.

    Article  Google Scholar 

  3. Assy N, Nasser G, Djibre A, et al. Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol. 2009;15(26):3217–27.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Göksoy E, Kapan M. İ.Ü. Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri. Hepato-Bilier Sistem ve Pankreas Hastalıkları. Sempozyum Dizisi. No: 28, Ocak 2002; s. 183–190.

    Google Scholar 

  5. American Cancer Society. Cancer facts & figures 2018. Atlanta: American Cancer Society; 2018.

    Google Scholar 

  6. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on the status of cancer, 1975–2014, featuring survival. J Natl Cancer Inst. 2017;109(9)

    Google Scholar 

  7. Hugh TJ, Kinsella AR, Poston GJ. Management strategies for colorectal liver metastases—Part I. Surg Oncol. 1997;6:19–30.

    Article  CAS  PubMed  Google Scholar 

  8. Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer. 2009;115(4):752–9.

    Article  PubMed  Google Scholar 

  9. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25:4575–80.

    Article  PubMed  Google Scholar 

  10. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18. discussion 318–321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Walter H, Thomas AL. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review. Br J Cancer. 2013;108(12):2417–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5.

    Article  PubMed  Google Scholar 

  13. National Comprehensive Cancer Network (NCCN) website. NCCN Clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf (Accessed on 30 January, 2019).

  14. Van Cutsem E, Cervantes A, Adam R, et al. ESMO Consensus Guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;8:1386–422.

    Article  Google Scholar 

  15. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.

    Article  CAS  PubMed  Google Scholar 

  16. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976–82.

    Article  CAS  PubMed  Google Scholar 

  17. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 09, 2018).

  18. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Capecitabine_monograph.pdf

  19. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Fluorouracil_monograph.pdf

  20. Loriot MA, Ciccolini J, Thomas F, et al. Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer. 2018;105(4):397–407.

    Article  PubMed  Google Scholar 

  21. http://www.bccancer.ca/drug-atabasesite/Drug%20Index/Oxaliplatin_monograph_1Dec2016.pdf

  22. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Irinotecan_monograph.pdf

  23. Saliba F, Hagipantelli R, Misset JL, et al. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol. 1998;16(8):2745.

    Article  CAS  PubMed  Google Scholar 

  24. Hu Z-Y, Yu Q, Pei Q, Guo C. Dose-dependent association between UGT1A1*28 genotype and ırinotecan-ınduced neutropenia: low doses also ıncrease risk. Clin Cancer Res. 2010;15:3832–42. https://doi.org/10.1158/1078-0432.CCR-10-1122.

    Article  CAS  Google Scholar 

  25. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767.

    Article  PubMed  Google Scholar 

  26. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. Epub 2014 Oct 9

    Article  CAS  PubMed  Google Scholar 

  27. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94(11):3314–9.

    Article  CAS  PubMed  Google Scholar 

  28. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56(4):918–28.

    Article  CAS  PubMed  Google Scholar 

  29. Farinati F, Rinaldi M, Gianni S, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000;89(11):2266–73.

    Article  CAS  PubMed  Google Scholar 

  30. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC Staging Classification. Semin Liver Dis. 1999;19(3):329–38.

    Article  CAS  PubMed  Google Scholar 

  31. Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for hepatocellular carcinoma: does it improve survival? Ann Surg Oncol. 2004;11(3):298–303.

    Article  PubMed  Google Scholar 

  32. National Comprehensive Cancer Network (NCCN) website. NCCN Clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf (Accessed on 30 January, 2019).

  33. Vogel A, Cervantes A, Chau I, et al. Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv238-iv255.

    PubMed  Google Scholar 

  34. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  PubMed  Google Scholar 

  35. Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  36. Kudo M, Finn RS, Qin S, et al., Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73.

    Article  CAS  PubMed  Google Scholar 

  37. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.

    Article  CAS  PubMed  Google Scholar 

  38. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nexavar (sorafenib) [product monograph]. Toronto, ON: Bayer Inc.; May 2013.

    Google Scholar 

  40. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Sorafenib_monograph.pdf

  41. Lenvima (lenvatinib) [product monograph]. Mississauga, ON: Eisai Limited; December 2018.

    Google Scholar 

  42. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Lenvatinib_monograph.pdf

  43. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Nivolumab_monograph.pdf

  44. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13(9):1001–11.

    Article  CAS  PubMed  Google Scholar 

  45. Boone SL, Jameson G, Von Hoff D, et al. Blackberry-induced hand-foot skin reaction to sunitinib. Invest New Drugs. 2009;27(4):389–90.

    Article  CAS  PubMed  Google Scholar 

  46. UpToDate website. Available at: https://www.uptodate.com/contents/cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy

  47. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59. Epub 2009 Jul 13

    Article  PubMed  Google Scholar 

  48. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer. 2009;7(1):20–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Feldt S, Schüssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer. 2012;48(7):974–81.

    Article  CAS  PubMed  Google Scholar 

  50. Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs. 2012;30(3):1055–64.

    Article  CAS  PubMed  Google Scholar 

  51. Figlin RA, de Souza P, McDermott D, et al. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha. Cancer. 2009;115(16):3651–60.

    Article  CAS  PubMed  Google Scholar 

  52. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.

    Article  CAS  PubMed  Google Scholar 

  53. UpToDate website. Available at: https://www.uptodate.com/contents/toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects

  54. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–30.

    Article  PubMed  CAS  Google Scholar 

  55. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412–9.

    Article  CAS  PubMed  Google Scholar 

  56. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501.

    Article  CAS  PubMed  Google Scholar 

  57. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012;104:93–113.

    Article  CAS  PubMed  Google Scholar 

  59. Ghatalia P, Je Y, Mouallem NE, et al. Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2015;93:257–76.

    Article  PubMed  Google Scholar 

  60. Shibata SI, Chung V, Synold TW, et al. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res. 2013;19:3631–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Shibata S, Longmate J, Chung VM, et al. A phase I and pharmacokinetic single agent study of pazopanib in patients with advanced malignancies and varying degrees of liver dysfunction (Abstract 2571). J Clin Oncol. 2010;28:221s.

    Article  Google Scholar 

  62. UpToDate website. Available at: https://www.uptodate.com/contents/toxicity-of-molecularly-targeted-antiangiogenic-agents-cardiovascular-effects

  63. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol. 2006;24:1329–31.

    Article  PubMed  Google Scholar 

  64. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234S.

    Article  CAS  PubMed  Google Scholar 

  65. Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA. 2004;292:1867–74.

    Article  CAS  PubMed  Google Scholar 

  66. Chintalgattu V, Patel SS, Khakoo AY. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin N Am. 2009;23:97–107.

    Article  Google Scholar 

  67. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239.

    Article  PubMed  Google Scholar 

  68. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Saf. 2013;36:295–316.

    Article  CAS  PubMed  Google Scholar 

  69. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer. 2015;112:296–305.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ministry of Health, Tepecik Training and Research Hospital, Izmir, Turkey

    Hüseyin Salih Semiz

  2. Dokuz Eylül University, Institute of Oncology, Izmir, Turkey

    İlhan Öztop

Authors
  1. Hüseyin Salih Semiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. İlhan Öztop
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hüseyin Salih Semiz .

Editor information

Editors and Affiliations

  1. School of Medicine, Dokuz Eylül University, izmir, Turkey

    Recep Bekiş

  2. Dokuz Eylül University, Izmir, Turkey

    Berna Polack

  3. School of Medicine, Hacettepe University, Ankara, Turkey

    Murat Fani Bozkurt

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Semiz, H.S., Öztop, İ. (2022). Systemic Treatments and Related Side Effects in Liver Tumors. In: Bekiş, R., Polack, B., Bozkurt, M.F. (eds) Radionuclide Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-97220-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-97220-2_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-97219-6

  • Online ISBN: 978-3-030-97220-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation